In support of this possibility, we found that there was no significant difference in the frequency and quantification of PPARγ+ cells or the level of PPARγ expression among CD11b+F4/80+ monocytes/macrophages (Supplementary Fig. S3a, b) between untreated and T007-injected tumor-bearing mice, and that levels of PPARδ expression in macrophages were comparable between naïve and tumor-bearing mice, and not affected by treatment with FGK or GSK (Supplementary Fig. S3c). This evidence concerns the gene PPARD and neoplasm.